GSK logo

GSK plc American Depositary Shares (Each representing two) (GSK)

$50.41

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GSK

Market cap

$102.92B

EPS

1.52

P/E ratio

12.5

Price to sales

1.72

Dividend yield

3.585%

Beta

0.455851

Price on GSK

Previous close

$50.45

Today's open

$51.23

Day's range

$50.38 - $51.43

52 week range

$45.81 - $61.70

Profile about GSK

CEO

Luke Miels

Employees

68629

Headquarters

London,

Exchange

New York Stock Exchange

Shares outstanding

2.02B

Issue type

American Depository Receipt

GSK industries and sectors

Healthcare

Pharmaceuticals

News on GSK

FDA grants accelerated approval to GSK's lung cancer drug

FDA grants accelerated approval to GSK's lung cancer drug

news source

Reuters • 2 hours ago

news preview

GSK: 3 Key Takeaways for Long-Term Investors

GSK started 18 phase 3 clinical trials in 2026. Specialty medicine sales grew 15% in the third quarter.

news source

The Motley Fool • 15 hours ago

news preview

GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms

GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Development David Redfern said at the Jefferies Healthcare Conference.

news source

MarketBeat • 9 hours ago

news preview

GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Guggenheim's Healthcare Innovation Conference.

news source

MarketBeat • Nov 9, 2026

news preview

GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and ​mNEXSPIKE and RSV shot mResvia of infringing ‌its patents, the companies said on Friday.

news source

Reuters • Nov 6, 2026

news preview

Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine

FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE: GSK)  that will use Alamar's NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions.

news source

GlobeNewsWire • Nov 3, 2026

news preview

GSK: The Gas Pedal Is Still Down, But Bumps Ahead

Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventory reductions and broader RSV demand issues.

news source

Seeking Alpha • Oct 30, 2026

news preview

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

news source

Zacks Investment Research • Oct 29, 2026

news preview

GSK beats third-quarter profit estimates, keeps annual targets

GSK beat third-quarter sales ‌and profit expectations on Wednesday, driven by demand for specialty medicines after the drugmaker began a strategic overhaul under CEO Luke Miels to accelerate growth and prepare for looming patent losses.

news source

Reuters • Oct 28, 2026

news preview

GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat

GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.

news source

Benzinga • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in GSK plc American Depositary Shares (Each representing two)

Open an M1 investment account to buy and sell GSK plc American Depositary Shares (Each representing two) commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GSK on M1